News
Stay up to date. The MLL Munich Leukemia Laboratory stands for innovation and the best leukemia diagnostics. Here you will find the latest research and study results related to hematological diagnostics and the therapy based on them, as well as other exciting news and events.
The magazine
Roman Möhlmann
at 20.03.2024
Minister of State Gerlach visits the MLL
Bavaria's Minister of Health Judith Gerlach visited MLL to find out about current trends and topics in technology-supported diagnosis and therapy. (Press Release)
Roman Möhlmann
at 22.02.2024
New framework conditions, new opportunities: Health Data Utilization Act, Digital Act, research data rooms and their consequences
The use of patient data from diagnostics and therapy holds potential for medical progress. The last few months have also been dominated by digitalization and artificial intelligence in the healthcare industry, and the turn of the year 2023/2024 was also characterized by numerous innovations in the legal and regulatory environment.
Dr. rer. nat. Christine Käppel
at 22.02.2024
Quality and sustainability are very important at MLL
Through rapid and targeted leukemia diagnostics, MLL works every day to provide patients worldwide with the best therapy. The focus here is on the quality of the analysis results. In addition, the MLL strives to fulfill its tasks in an environmentally friendly and sustainable manner. Read the article to find out how quality and sustainability are compatible at MLL.
Roman Möhlmann
at 01.02.2024
Innovation competition: MLL Munich leukemia laboratory once again among the TOP 100
As a technology and industry pioneer, the MLL Munich Leukemia Laboratory once again receives the prestigious award for its innovative strength.
Roman Möhlmann
at 18.01.2024
Healthcare in times of war: help for Ukrainian haematology patients
The MLL Munich Leukemia Laboratory supports the "Help for Ukrainian Hematology Patients (HUP)" network, a global initiative to maintain and improve hematology care in Ukraine. The aim is to set up hematology centers and establish hematopoietic cell transplantation programs in times of war. As part of the project, blood or bone marrow samples from Ukraine are sent to the MLL on a weekly basis, and the senders and hospitals there receive the results free of charge within a few days. Over 580 samples from Ukraine have already been processed at the MLL and 2300 different hematological tests have been carried out. (Press release)
Roman Möhlmann
at 13.01.2024
"Fighting Cancer with AI" - Artificial intelligence in the fight against cancer
Prof. Torsten Haferlach: "Medicine is facing the next revolution when processes, diagnostics and treatment are increasingly supported by AI. Staff can be relieved and the quality of diagnoses and treatment options optimized. However, the framework conditions must be right. With a view to the data protection vs. patient protection debate, innovation-inhibiting hurdles in the use of data for research must be reduced if we want to create a sustainably networked healthcare data infrastructure." (Press release and video recording of the conference session)
Dr. rer. nat. Constanze Kühn
at 22.02.2024
More precise relapse prognosis for CML patients: Cell line-specific detection in measurable residual disease
A new study by Pagani et al. examines the role of cell line-specific measurement of BCR::ABL1 transcripts by quantitative PCR in different immune cell populations with a view to more precise methods for predicting relapse after the end of therapy. According to the study, the detection of BCR::ABL1 DNA in granulocytes and T cells after discontinuation of therapy could be a better predictor of relapse than detection in total leukocytes.
Dr. rer. nat. Constanze Kühn
at 20.12.2023
MLL at the 65th ASH Annual Meeting & Exposition - a follow-up report
From December 9-12, 2023, the 65th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in San Diego, California - and MLL was represented again this year. We have summarized highlights of the 15 MLL contributions at the ASH for you in this article.
Dr. Wencke Walter
at 20.12.2023
Every cell counts - establishing single cell sequencing at the MLL
Starting with the analysis of a single cell, the field of single-cell sequencing has now developed into a high-throughput technology with great potential for clinical applications.Significant improvements in methodology have made it possible to study gene expression, epigenetic heterogeneity and subclonal DNA architecture with a resolution that is almost unattainable with mass sequencing.Naturally, we are also interested in such an innovative method and have therefore now established single-cell sequencing at the MLL.
Dr. rer. nat. Veronika Ecker
at 16.10.2023
Sorter enrichment of small B-NHL clones for NGS analyses
Currently, the immunophenotyping team at MLL is establishing a sorter-based method to reliably offer molecular genetic testing by NGS for B-cell lymphomas in the future, even with low bone marrow infiltration or washout into the peripheral blood (<5% of leukocytes). All important background information can be found in the current newsletter.
PD Dr. med. Gregor Hörmann, PhD
at 09.08.2023
Clonal hematopoiesis risk score
Counseling patients with clonal hematopoiesis is an increasing challenge in the workup of unclear cytopenias. A recently published Clonal Hematopoiesis Risk Score (CHRS) allows prediction of 10-year progression risk based on the type and number of gene mutations and simple blood count variables. The results emphasize the relevance of including molecular genetic testing in the workup of unclear cytopenias and provide guidance in interpreting the results for patient management.
Dr. med. Christian Pohlkamp
at 09.08.2023
MLL staging diagnostics for unclear cytopenia
One of the most frequent questions in hematological practices and hospitals is the clarification of cytopenias. The causes are manifold, especially in older patients, and can be benign or malignant. After bone marrow collection, it is often not possible to assess which diagnostic methods are useful for clarifying the potential underlying bone marrow disease when the material is sent to a specialized hematology laboratory. Therefore, MLL offers the option to order "stepwise diagnostics". In this article we have compiled all the important information on this.
Dr. rer. nat. Isolde Summerer
at 06.10.2022
Chromosome Analysis 5.0 – Automation, Digitization and Artificial Intelligence
Chromosome analysis is an essential part of the diagnostics of malignant hematological diseases. It plays an important role in confirming the diagnostics, classification, prognosis assessment and therapy planning. The method is considered time-consuming and demanding, both laboratory-wise and in terms of evaluation and reporting. In addition to the continuous expansion of the automation of laboratory processes, the use of artificial intelligence (AI) in chromosome analysis in particular enables a significant reduction in the reporting time as well as a more objective and sensitive assessment of chromosomal changes.
Dr. rer. nat. Constanze Kühn
at 16.08.2021
MTLAs, doctors and artificial intelligence at MLL – a good team!
Dr. med. Christian Pohlkamp
at 06.08.2021
MLL and Institute of AI for Health of the Helmholtz Center of Munich Announce Research Collaboration
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 30.09.2020
BELUGA - A Prospective, Registered Study on the Use of Artificial Intelligence (AI) in Hematology
at 18.02.2020
The Use of Artificial Intelligence at MLL Munich Leukemia Laboratory
Niroshan Nadarajah
at 18.11.2019
MLLi:ir - A diagnostic interpretation report for NGS data
Dr. Wencke Walter
at 11.01.2024
Research Report 2023
This year was marked by various challenges, including war, natural disasters, and inflation, yet we managed to make significant strides in research. Our research report reflects the tireless dedication and innovative spirit of MLL's team as we continue to push the boundaries of knowledge in the field of hematology.
Dr. Wencke Walter
at 09.01.2023
Research Report 2022
Those who know us know that we always look ahead, push boundaries, and rarely stand still. We have reviewed the last scientific year and summarized our research highlights in the new Research Report 2022. Feel free to get caught up in our own passion and immerse yourself in our research with us. In 2022, we were once again energized, curious, and enthusiastic about advancing the best possible leukemia diagnostics for our patients. To further facilitate reading and to better convey our data, we have included various graphical representations and summaries and we hope you enjoy the content.
Dr. Wencke Walter
at 15.03.2022
Leukaemia diagnosis – Realising the potential of whole transcriptome sequencing
In AML and ALL the application of WHO classification and ELN guidelines requires a plethora of methods to determine the diagnostic and prognostic subgroup. Especially in ALL, many different subtypes have been described, which makes accurate diagnosis a challenge. However, in recent years, whole genome and whole transcriptome sequencing have emerged as comprehensive high-throughput techniques that allow for an accurate genetic characterization. This identification of patients’ genetic fingerprint is key to a precise diagnosis and the design of personalised cancer treatments.
Dr. Wencke Walter
at 28.12.2021
Research Report 2021
Dr. Wencke Walter
at 10.02.2020
Genomic & Transcriptomic Data Visualization
Dr. Wencke Walter
at 04.12.2019
Analysis of pharmacogenomic variants by WGS data for AML patients with altered response to treatment
22.02.2024
Training for our senders and referring physicians 2024
Save the Date: The MLL and the LMU Ludwig-Maximilians-University (Medical Clinic and Polyclinic III) invite you to an advanced training course on "Sickle cell disease and thalassemia - diagnostics and new therapy concepts" on June 19, 2024 from 5:00 to 7:00 pm. Participation will be possible on site or virtually, further information will follow shortly (language: German).
20.12.2023
MLL Academy 2024
The next MLL Academy will take place from 22.04. to 24.04.2024. In the three-day workshop on the topic: "State of the art diagnostics in hematological malignancies", the twelve participants can expect a mix of theoretical and practical content as well as joint discussion rounds on the diagnosis of leukemias and lymphomas. Registration is possible until 01.03.2024 (Language: German).
You may also be interested in
Your contact person
»Transparent communication both internally and externally is important to us.«
Roman Möhlmann